Vanguard Global Advisers
COYA icon

Vanguard Global Advisers’s Coya Therapeutics COYA Stock Holding History

Vanguard Global Advisers’s Portfolio COYA Stock Details COYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.4K Hold
5,879
– – ﹤0.01% 3184
2026
Q1 		$23.2K Buy
+5,879
New +$27.5K ﹤0.01% 3263

Other funds holding COYA

DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
PMG
Private Management Group Irvine, California $3.8B AUM 23.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Vanguard Global Advisers's COYA Position: Q2 2026 in Review

Vanguard Global Advisers held its Coya Therapeutics (COYA) position steady in Q2 2026 at 5,879 shares worth $34.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3184.

Vanguard Global Advisers first reported a position in COYA in Q1 2026 and has held it in 2 quarters since. 53 funds tracked by Wall St. Rank hold COYA as of Q2 2026.

  • Vanguard Global Advisers held 5,879 shares of Coya Therapeutics worth $34.4K as of Q2 2026.
  • Vanguard Global Advisers left its Coya Therapeutics share count unchanged in Q2 2026.
  • Coya Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3184 holding.
  • Vanguard Global Advisers first reported a position in Coya Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 53 funds tracked by Wall St. Rank held Coya Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.